SpaceX's Dragon capsule docked onto the ISS and will return to Earth in February. Photo via SpaceX

The two astronauts stuck at the International Space Station since June welcomed their new ride home with Sunday’s arrival of a SpaceX capsule.

SpaceX launched the rescue mission on Saturday with a downsized crew of two astronauts and two empty seats reserved for Butch Wilmore and Suni Williams, who will return next year. The Dragon capsule docked in darkness as the two craft soared 265 miles (426 kilometers) above Botswana.

NASA switched Wilmore and Williams to SpaceX following concerns over the safety of their Boeing Starliner capsule. It was the first Starliner test flight with a crew, and NASA decided the thruster failures and helium leaks that cropped up after liftoff were too serious and poorly understood to risk the test pilots’ return. So Starliner returned to Earth empty earlier this month.

The Dragon carrying NASA’s Nick Hague and the Russian Space Agency’s Alexander Gorbunov will remain at the space station until February, turning what should have been a weeklong trip for Wilmore and Williams into a mission lasting more than eight months.

Two NASA astronauts were pulled from the mission to make room for Wilmore and Williams on the return leg.

“I just want to say welcome to our new compadres,” Williams, the space station commander, said once Hague and Gorbunov floated inside and were embraced by the nine astronauts awaiting them.

Hague said it was a smooth flight up. “Coming through the hatch and seeing all the smiles, and as much as I've laughed and cried in the last 10 minutes, I know it's going to be an amazing expedition," he said.

NASA likes to replace its station crews every six months or so. SpaceX has provided the taxi service since the company’s first astronaut flight in 2020. NASA also hired Boeing for ferry flights after the space shuttles were retired, but flawed software and other Starliner issues led to years of delays and more than $1 billion in repairs.

Starliner inspections are underway at NASA’s Kennedy Space Center, with post-flight reviews of data set to begin this week.

“We’re a long way from saying, ‘Hey, we’re writing off Boeing,’” NASA’s associate administrator Jim Free said at a pre-launch briefing.

The arrival of two fresh astronauts means the four who have been up there since March can now return to Earth in their own SpaceX capsule in just over a week, bringing the station's crew size back down to the normal seven. Their stay was extended a month because of the Starliner turmoil.

Although Saturday’s liftoff went well, SpaceX said the rocket’s spent upper stage ended up outside its targeted impact zone in the Pacific because of a bad engine firing. The company has halted all Falcon launches until it figures out what went wrong.was extended a month because of the Starliner turmoil.

A new pharmacy startup has officially launched in Houston. Photo courtesy of Capsule

Digital pharmacy launches in Houston to address access with same-day delivery

launching in HOU

A health tech company has officially launched locally to serve as a digital pharmacy platform. The company is aiming to simplify the process for customers.

Capsule has launched in Houston to address access-challenged pharmacy deserts as well as allow for discreet delivery of frequently stigmatized medications. The company also prioritizes better communications than standard pharmacy service.

"Capsule's mission has always been to build a pharmacy that works for everyone," says Eric Kinariwala, founder and CEO of Capsule, in a news release. "We believe that the core pharmacy experience is fundamentally broken for the hundreds of millions of Americans who take medication regularly, so we set out to rebuild that experience from the inside out."

Capsule's custom software prevents common issues out-of-stock medications, long wait times, and lack of price transparency, as well as improves communications. Customers can sign up for the service — which includes same-day delivery within all of Harris County and parts of Chambers, Fort Bend, Galveston, and Montgomery counties — and have their physician send their prescriptions to Capsule. The company accepts all major insurance plans, including Medicare and Medicaid.

One problem that Capsule is attempting to solve is access to pharmaceuticals. According to the release, half of prescriptions in America go unfilled resulting in $300 billion in additional healthcare costs. One factor contributing to this problem is access.

"We know that there is a direct link between proximity to a pharmacy and prescription fill rates," Kinariwala says. "And the consequences of failing to fill vital prescriptions can be dire. Capsule is a part of the solution."

In Houston, pharmacy deserts disproportionately affect minorities. Over 40 percent of Hispanic residents and 70 percent of Black residents live a mile or more away from a pharmacy. According to USA Rx data, Harris County has 1.39 pharmacies per 10,000 residents, which is below the national average of 2.4.

"Capsule's long-term ambition is to create a hub where consumers can access all of their healthcare needs in a single, simple, holistic place," says Kinariwala. "We're doing that in a way that brings together everybody in healthcare versus trying to own all of those things ourselves. Just like you buy a cell phone and choose apps, people will be able to access Capsule's digital pharmacy, as well as a best-in-class curated set of products and services to meet all of their healthcare needs from within a single app."

Eric Kinariwala is the founder and CEO of Capsule. Photo courtesy of Capsule

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup debuts bio-based 'leather' fashion collection in Milan

sustainable fashion

Earlier this month, Houston-based Rheom Materials and India’s conscious design studio Econock unveiled a collaborative capsule collection that signaled more than just a product launch.

Hosted at Lineapelle—long considered the global epicenter of the world's premier leather supply chain—in the vaulted exhibition halls of Rho-Fiera Milano, the collection centered around Rheom’s 91 percent bio-based leather alternative, Shorai.

It was a bold move, one that shifted sustainability from a concept discussed in panel sessions to garments that buyers could touch and wear.

The collection featured a bomber-style jacket, an asymmetrical skirt and a suite of accessories—all fabricated from Shorai.

The standout piece, a sculptural jacket featuring a funnel neck and dual-zip closure, was designed for movement, challenging assumptions about performance limitations in bio-based materials. The design of the asymmetrical skirt was drawn from Indian armored warrior traditions, according to Rheom, with biodegradable corozo fasteners.

Built as a modular wardrobe rather than isolated pieces, the collection reflects a shared belief between Rheom and Econock in designing objects that adapt to daily life, according to the companies.

The collection was born out of a new partnership between Rheom and Econock, focused on bringing biobased materials to the market. According to Rheom, the partnership solves a problem that has stalled the adoption of many next-gen textiles: supply chain friction.

While Rheom focuses on engineering scalable bio-based materials, New Delhi-based Econock brings the complementary design and manufacturing ecosystem that integrates artisans, circular materials and production expertise to translate the innovative material into finished goods.

"This partnership removes one of the biggest barriers brands face when adopting next-generation materials,” Megan Beck, Rheom’s director of product, shared in a news release. “By reducing friction across the supply chain, Rheom can connect brands directly with manufacturers who already know how to work with Shorai, making the transition to more sustainable materials far more accessible.”

Sanyam Kapur, advisor of growth and impact at Econock, added: “Our partnership with Rheom Materials represents the benchmark of responsible design where next-gen materials meet craft, creativity, and real-world scalability.”

Rheom, formerly known as Bucha Bio, has developed Shorai, a sustainable leather alternative that can be used for apparel, accessories, car interiors and more; and Benree, an alternative to plastic without the carbon footprint. In 2025, Rheom was a finalist for Startup of the Year in the Houston Innovation Awards.

Shorai is already used by fashion lines like Wuxly and LuckyNelly, according to Rheom. The company scaled production of the sugar-based material last year and says it is now produced in rolls that brands can take to market with the right manufacturer.

Houston startup debuts leather alternative fashion collection in Milan

Houston clean energy co. secures $100M to deploy tech on global scale

Going Global

Houston-based Utility Global has raised $100 million in an ongoing Series D round to globally deploy its decarbonization technology at an industrial scale.

The round was led by Ara Partners and APG Asset, according to a news release. Utility plans to use the funding to expand manufacturing, grow its teams and support its commercial developments and partnerships.

“This financing marks a critical step in Utility’s transition from a proven technology to full-scale global commercial execution,” Parker Meeks, CEO and president of Utility Global, said in the release. “Industrial customers are no longer looking for pilots or promises; they need deployable solutions that work within existing assets and deliver true economic industrial decarbonization today that is operationally reliable and highly scalable. Utility’s technology produces both economic clean hydrogen and capture-ready CO2 streams, and this capital enables us to scale and deploy that impact globally with speed, discipline, and rigor.”

Utility Global's H2Gen technology produces low-cost, clean hydrogen from water and industrial off-gases without requiring electricity. It's designed to integrate into existing industrial infrastructure in hard-to-abate assets in the steel, refining, petrochemical, chemical, low-carbon fuels, and upstream oil and gas sectors.

“Utility is tackling one of the most difficult challenges in the energy transition: decarbonizing hard‑to‑abate industrial sectors,” Cory Steffek, partner at Ara Partners and Utility Global board chair, said in the release. “What sets Utility apart is its ability to compete head‑to‑head with conventional fossil‑based solutions on cost and reliability, even as it materially reduces emissions. With this new funding, Utility is well-positioned for its next chapter of commercial growth while maintaining the technical excellence and capital discipline that have defined its development to date.”

Utility Global reached several major milestones in 2025. After closing a $53 million Series C, the company agreed to develop at least one decarbonization facility at an ArcelorMittal steel plant in Brazil. It also signed a strategic partnership with California-based Kyocera International Inc. to scale global manufacturing of its H2Gen electrochemical cells.

The company also partnered with Maas Energy Works, another California company, to develop a commercial project integrating Maas’ dairy biogas systems with H2Gen to produce economical, clean hydrogen.

"These projects were never intended to stand alone. They anchor a deep and growing pipeline of commercial projects now in development globally across steel, refining, chemicals, biogas and other hard-to-abate sectors worldwide, Meeks shared in a 2025 year-in-review note. He added that 2026 would be a year of "focused acceleration to scale."

---

This article originally appeared on EnergyCapitalHTX.com.

Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

  • 21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
  • 68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.